Abstract: The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions.

Abstract: The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions.

Abstract: The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions.

Abstract: The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies.

Abstract: The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions.

Abstract: The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies.

Abstract: The disclosure includes methods for the identification of chemotherapeutic agents that selectively reduce the growth or the survival of genotoxically stressed DNA damage checkpoint deficient tissue, such as irradiated cancerous tissue. The methods involve the use of genotoxically-stressed tissue(s) that are deficient in one or more DNA damage checkpoints. The disclosure also provides kits for performing the disclosed methods. The disclosure also includes chemotherapeutic agents that selectively reduce the growth or the survival of genotoxically stressed DNA damage checkpoint deficient tissue, such as irradiated cancerous tissue. The disclosure also includes methods of treatment or management of cancer, tumor formation, other conditions involving abnormal proliferation, or cell-cycle diseases or disorders.

Abstract: The novel FLJ11011 gene encoding a human ubiquitin-conjugating (E2) enzyme as well as gene fragments, coding sequences, mRNA variants and encoded proteins are disclosed. Additionally, methods of diagnosing and treating a patient that has or is suspected of having Fanconi's anemia or increased susceptibility to cancer or diminished capability of DNA repair. Additionally, methods of identifying compounds with the potential to treat or ameliorate Fanconi's Anemia are provided.